GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » Construction In Progress

KalVista Pharmaceuticals (FRA:4XC1) Construction In Progress : €0.00 Mil (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Construction In Progress?


KalVista Pharmaceuticals Construction In Progress Historical Data

The historical data trend for KalVista Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Construction In Progress Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

KalVista Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


KalVista Pharmaceuticals (FRA:4XC1) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (FRA:4XC1) Headlines

No Headlines